ANJALI ADVANI (CLEVELAND)
NOVEL THERAPIES FOR T-ALL/LL
Anjali Advani, MD
Historically, relapsed/ refractory acute lymphoblastic leukemia (ALL) has been associated with a poor
prognosis. Significant advances have been made in B-ALL with antibody drug conjugates, bispecific
antibodies, and chimeric antigen receptor T cells. This progress has been lacking in T-ALL. However,
things are starting to change. This talk will focus on 3 new therapeutic targets in T-ALL: aldo-keto
reductase family 1 member C3 (AKR1C3), CD38, BCL-2, and BCL-XL.
1. Evans K, Duan J, Pritchard T, et al. OBI-3424, a novel AKR1C3-activated prodrug exhibits potent efficacy
against preclinical models of T-ALL. Clin Cancer Res 2019; 25(14): 4493-4503.
2. Chonghaile TN, Roderick JE, Glenfield C, et al. Maturation stage of T-cell acute lymphoblastic leukemia
determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov 2014; 4(9):
1074-1087.
3. Bride KL, Vincent TL, Im S-Y, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic
leukemia. Blood 2018; 131(9): 995-999.